HEMAGEN DIAGNOSTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Show all filings for HEMAGEN DIAGNOSTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HEMAGEN DIAGNOSTICS INC 1-Oct-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informa...
Click here to read the whole Article (external link)

Hemagen Successfully Completes Its Offer to Exchange 8% Senior Subordinated Secured Convertible Notes Due September 30, 2009

COLUMBIA, Md.--(BUSINESS WIRE)--William P. Hales, Chairman, President and CEO, of Hemagen Diagnostics, Inc., (OTCBB: HMGN - News) (the “Company”) today announced the successful completion of its Exchange Offer for $4,049,858.01 in principal amount of the outstanding 8% Senior Subordinated Secured Convertible Notes due September 30, 2009 (the “Old Notes”). Those tendering in the Exchange Offer received new 8% Senior Subordinated Secured Convertible Notes due September 30, 2014 (the “New Notes”) having the same principal amount as the Old Notes tendered for exchange. The Exchange Offer expired on Wednesday September 30, 2009, at Midnight and is effective as of that date. The Company has accepted all Old Notes tendered for exchange. This News Bulletin is neither an offer to purchase nor a solicitation of an offer to sell securities of Hemagen Diagnostics, Inc. The exchange offer will be made only through and upon the terms and conditions described in Hemagen Diagnostics, Inc’s, Offering Memorandum dated September 1, 2009, and related letter of transmittal. Hemagen has filed a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission. The Tender Offer Statement (including an offering circular, a related letter of transmittal and other offering documents) contains important information that should be read carefully before any decision ...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Show all filings for HEMAGEN DIAGNOSTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HEMAGEN DIAGNOSTICS INC 1-Sep-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informat...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Refer to "Forward Looking Statements" following the Index in front of this Form 10-Q. Overview Hemagen Diagnostics, Inc. is a biotechnology company that develops, manufactures, and markets approximately 68 FDA-cleared proprietary medical diagnostic test kits. Hemagen has two different product lines. The Virgo® product line of diagnostic test kits is used to aid in the diagnosis of certain autoimmune and infectious diseases, using ELISA, Immunoflourescence, and hemagglutination technology. The Analyst® product line is an FDA-cleared clinical chemistry analyzer system, including consumables, that is used to measure important constituents in human and animal blood. The Company sells its products both directly and through distributors to reference labs, physicians, veterinarians, clinical laboratories and blood banks. The Company also sells its products on a private-label basis through multinational distributors. The Company was incorporated in 1985 and became a public company in 1993. Hemagen's principal office is located at 9033 Red Branch Road, Columbia, Maryland 21045 and the telephone number is (443) 367-5500. Hemagen maintains a website at www.hemagen.com. Investors can obtain copies of our filings with the Securities and Exchange Commission from this site free of charge as well as from the Securities and Exchange Commission website at www.sec.gov. Critical Accounting Policies We have identified certain accounting policies as critical to our business operations and the understanding of our results of operations. The impact and any associated risks related to the identified critical accounting policies on our business operations are discussed in our Annual Report on Form 10-KSB for the fiscal year ended September 30, 2008 filed with the Securities and Exchange Commission. Results of Operations The Three Month Period Ended Jun...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Refer to "Forward Looking Statements" following the Index in front of this Form 10-Q. Overview Hemagen Diagnostics, Inc. is a biotechnology company that develops, manufactures, and markets approximately 68 FDA-cleared proprietary medical diagnostic test kits. Hemagen has two different product lines. The Virgo® product line of diagnostic test kits is used to aid in the diagnosis of certain autoimmune and infectious diseases, using ELISA, Immunoflourescence, and hemagglutination technology. The Analyst® product line is an FDA-cleared clinical chemistry analyzer system, including consumables, that is used to measure important constituents in human and animal blood. The Company sells its products both directly and through distributors to reference labs, physicians, veterinarians, clinical laboratories and blood banks. The Company also sells its products on a private-label basis through multinational distributors. The Company was incorporated in 1985 and became a public company in 1993. Hemagen's principal office is located at 9033 Red Branch Road, Columbia, Maryland 21045 and the telephone number is (443) 367-5500. Hemagen maintains a website at www.hemagen.com. Investors can obtain copies of our filings with the Securities and Exchange Commission from this site free of charge as well as from the Securities and Exchange Commission website at www.sec.gov. Critical Accounting Policies We have identified certain accounting policies as critical to our business operations and the understanding of our results of operations. The impact and any associated risks related to the identified critical accounting policies on our business operations are discussed in our Annual Report on Form 10-KSB for the fiscal year ended September 30, 2008 filed with the Securities and Exchange Commission. Results of Operations The Three Month Period ...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia

Show all filings for HEMAGEN DIAGNOSTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HEMAGEN DIAGNOSTICS INC 30-Apr-2009Entry into a Material Definitive Agreement, Creation of a Direct Financia Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All inf...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Certain statements in this report that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Any forward-looking statement speaks only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made or otherwise. Forward-looking statements may be identified by words such as "estimates", "anticipates", "projects", "plans", "expects", "intends", "believes", "should", and similar expressions and the negative versions thereof and by the context in which they are used. Statements concerning the establishments of reserves and adjustments for dated and obsolete products, expected financial performance, on-going business strategies and possible future action which Hemagen intends to pursue to achieve strategic objectives constitute forward-looking information. The sufficiency of such charges, implementation of strategies and the achievement of financial performance are each subject to numerous conditions, uncertainties and risk factors. Factors which could cause actual performance to differ materially from these forward-looking statements, include, without limitation, management's analysis of Hemagen's assets, liabilities and operations, the failure to sell date-sensitive inventory prior to its expiration, competition, new product development by competitors which could render particular products obsolete, the inabi...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 8-K, Change in Directors or Principal Officers

Show all filings for HEMAGEN DIAGNOSTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HEMAGEN DIAGNOSTICS INC 3-Feb-2009Change in Directors or Principal Officers Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purp...
Click here to read the whole Article (external link)

HEMAGEN DIAGNOSTICS INC Files SEC form 10KSB, Annual Report

Item 6. Management's Discussion and Analysis or Plan of Operation. Refer to "Forward Looking Statements" following the Index in the front of this Form 10-KSB. Overview Historically, Hemagen has concentrated its efforts on developing, manufacturing and marketing medical diagnostic test kits used to aid in the diagnosis of certain diseases and for assessing general health conditions. Hemagen has approximately 68 different test kits available that are 510(K) cleared for sale in the United States by the FDA, as well as other products that are not required to be FDA cleared that it sells. During the year, Hemagen sold the assets of its wholly-owned subsidiary, Reagents Applications Inc., a clinical chemistry reagent manufacturing business located in San Diego, CA. The sale was consummated on October 8, 2007. The Company's decision to sell the assets of Reagents Applications Inc. was made after careful consideration of an offer received for the business, and after considering the resources required to operate the business, the challenges associated with the geographic location, the size of the business and the opportunity to develop its other product lines. Management has been working to take the appropriate actions to improve the management and operations of the Company while striving to achieve sustained profitability. There can be no assurance that any of the previously discussed actions management is taking will achieve the desired results. However, management believes that as a direct result of these actions, cash flow from operations, the cash on hand at September 30, 2008 and its line of credit availability will be sufficient to finance its operations for fiscal 2009. See the "Recent Developments" section on page 3. At September 30, 2008, Hemagen had $98,799 of unrestricted cash, trade accounts receivable (net) of $866,306, a negative working deficit of $2,225,607 and a current ratio of .6 to 1.0. Included in the calculations of working ca...
Click here to read the whole Article (external link)